Close
Novotech
Jabsco PureFlo 21 Single Use

Omya acquires Galderma-Spirig site

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Structural Pricing Pressure is Reshaping Pharma in 2026

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.

Merck Targets $70B Revenue in 2026 with Cidara Deal

Merck’s roughly $9.2 billion acquisition of Cidara Therapeutics and its $70 billion revenue ambition mark a strategic pivot toward respiratory vaccines and antivirals. Explore how this deal reshapes Merck’s portfolio and signals a broader industry shift toward targeted M&A to offset patent cliffs.

U.S. Drug Pricing Reset Becomes Real in 2026

In 2026, U.S. drug pricing finally moved from policy debate to P&L impact. The first set of Medicare “maximum fair prices” and Most‑Favoured‑Nation–style reference pricing are reshaping pharma margins and launch strategies.
- Advertisement -

Following Galderma-Spirig’s decision to close their Egerkingen site in September 2017, Omya International, based in neighboring Oftringen, will move research and development activities to the site. To this end, Omya is acquiring the property from Galderma-Spirig’s parent company, Nestlé Skin Health.

In addition to acquiring the property, including all buildings and facilities, Omya intends to acquire Spirig Pharma’s Cosmospheres business unit, which develops and manufactures high-quality cellulose-based additives for the cosmetics industry. Omya will offer continued employment to the employees in this business area. In addition, the continued employment of facility management and maintenance staff is reviewed.

Growth in Oftringen and Egerkingen In recent years, Omya headquarters in Oftringen have grown strongly and have reached their capacity. With the relocation of research and development activities to neighboring Egerkingen, the bottleneck at the headquarters will be eliminated long-term without further construction and space will be made available for the company’s strongly growing activities.

The buildings in Egerkingen have a modern technical infrastructure, which are suitable for research and development activities without substantial structural interventions. The Cosmospheres business unit, which Omya intends to acquire, would complement and expand Omya’s offering, as Omya already is a supplier of raw materials for the cosmetics and pharmaceutical industries. In the end, up to 350 full-time jobs will be located at the new site.

Omya
Omya is a leading global producer of industrial minerals – mainly fillers and pigments derived from calcium carbonate and dolomite – and a worldwide distributor of specialty chemicals. The company provides a wealth of product solutions that contribute to its customers’ competitiveness and productivity in multiple industries such as Construction, Printing & Writing, Technical Polymers, Packaging, Food, Personal & Home Care, Pharmaceuticals, Agriculture and Forestry, Water and Energy.

Founded in 1884 in Switzerland, Omya has a global presence extending to more than 175 locations in over 50 countries with 8,000 employees. Committed to implementing the principles of sustainability at all company levels, Omya provides added value products and services from responsibly sourced materials to meet the essential needs of current and future generations. www.omya.com

Latest stories

Related stories

Structural Pricing Pressure is Reshaping Pharma in 2026

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.

Merck Targets $70B Revenue in 2026 with Cidara Deal

Merck’s roughly $9.2 billion acquisition of Cidara Therapeutics and its $70 billion revenue ambition mark a strategic pivot toward respiratory vaccines and antivirals. Explore how this deal reshapes Merck’s portfolio and signals a broader industry shift toward targeted M&A to offset patent cliffs.

U.S. Drug Pricing Reset Becomes Real in 2026

In 2026, U.S. drug pricing finally moved from policy debate to P&L impact. The first set of Medicare “maximum fair prices” and Most‑Favoured‑Nation–style reference pricing are reshaping pharma margins and launch strategies.

White House-Big Pharma Tariff and Pricing Deals in 2026

In early 2026, the White House struck a series of tariff and pricing deals with major pharma firms, linking lower prices for GLP‑1 and other drugs to tariff relief and new distribution channels. Explore how these arrangements are reshaping U.S. pharma pricing, access and global spillovers.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »